Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell
death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies …

Background Since 2011 six immune checkpoint inhibitors (ICI) have been approved to treat
patients with many advanced solid tumor and hematological malignancies to improve their …

Background Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective
treatment option for metastatic melanoma as well as for other cancer entities. They act via …

Immune checkpoint inhibitors block the checkpoint molecules. Different types of cancer
immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies …

Hypophysitis is a heterogeneous condition that leads to inflammation of the sella and/or
suprasellar region, potentially resulting in hormonal deficiencies and/or mass effects. A …

In recent years, the development of immunotherapy has constituted a revolution in the
therapy for many cancers, with a specific toxicity profile including endocrine immune-related …

Immune checkpoint inhibitors (ICIs) are novel anticancer agents, recently introduced with the
aim of boosting the immune response against tumors. ICIs are monoclonal autoantibodies …

Purpose of review With the increasing use of immune checkpoint inhibitors in cancer therapy
radiographic profiling of frequent and serious immune-related adverse events (irAEs) …

Simple Summary Immune checkpoint inhibitors currently represent the standard of care for
the treatment of different tumor types and have also been proven to be effective in several …

Neurological complications of cancer and of anticancer treatments can be substantially
disabling to patients, especially with classic chemotherapies. As a rare but important …